Physician profile
Sindhu Jacob
NPI 1265540827
$4,590.11
in general payments reported to CMS, 2019-2025
43 companies · $2,194 in 2025
The $2,194 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $273 · 2021: $312 · 2022: $213 · 2023: $389 · 2024: $918 · 2025: $2,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,427 · Gift: $59.40 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,426.79 |
| Gift | $59.40 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $545.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $430.90 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $404.31 | 2019-2025 | |
| Amgen INC. | $283.97 | 2020-2025 | Tepezza, Evenity, Prolia |
| Kyowa Kirin, INC. | $227.12 | 2023-2025 | Crysvita |
| Lilly USA, LLC | $191.07 | 2020-2025 | Mounjaro, Jardiance |
| Amneal Pharmaceuticals LLC | $183.35 | 2023-2025 | Unithroid |
| Abbott Laboratories | $182.21 | 2019-2024 | Freestyle Libre 3, Freestyle Libre |
| Tandem Diabetes Care, INC. | $136.83 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $134.75 | 2025 | Yorvipath |
| Ibsa Pharma INC. | $131.61 | 2023-2025 | Tirosint, Licart, Flector |
| Xeris Pharmaceuticals, INC. | $130.18 | 2022-2025 | Gvoke Hypopen |
| Dexcom, INC. | $129.82 | 2019-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $118.80 | 2020-2023 | Afrezza |
| Cequr Corporation | $117.92 | 2021-2025 | Cequr Simplicity |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $103.53 | 2025 | Isturisa |
| Corcept Therapeutics | $100.09 | 2020-2025 | Korlym |
| Madrigal Pharmaceuticals | $97.43 | 2025 | Rezdiffra |
| Abbvie INC. | $83.41 | 2021-2025 | |
| Beta Bionics, INC. | $81.30 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $80.39 | 2023-2025 | |
| Insulet Corporation | $79.22 | 2024-2025 | Omnipod |
| Neurocrine Biosciences, INC. | $57.38 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.34 | 2025 | Jardiance |
| Tolmar, INC. | $48.65 | 2024 | |
| Glaxosmithkline, LLC. | $43.93 | 2025 | Shingrix, Arexvy |
| Medtronic, INC. | $33.73 | 2021-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $33.41 | 2019-2021 | |
| Rhythm Pharmaceuticals, INC. | $32.89 | 2025 | Imcivree |
| Acella Pharmaceuticals, LLC | $30.69 | 2024-2025 | NP Thyroid 60 |
| Averitas Pharma INC. | $28.13 | 2024 | Qutenza |
| Sequel Med Tech, LLC | $27.52 | 2025 | Twiist |
| Esperion Therapeutics, INC. | $26.50 | 2020 | |
| Pfizer INC. | $24.54 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.96 | 2025 | |
| Amarin Pharma, INC. | $23.93 | 2022 | |
| Horizon Therapeutics Plc | $23.17 | 2019 | |
| Companion Medical, INC. | $21.15 | 2019 | |
| Zealand Pharma US, INC. | $19.13 | 2021 | |
| Abiomed | $18.67 | 2024 | Impella |
| Ascensia Diabetes Care US INC. | $17.94 | 2024 | |
| Acerus Pharmaceuticals Corporation | $14.81 | 2020 | |
| Shire North American Group INC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindhu Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.